59 / 69
59
37.
Hasford J, Pfirrmann M, Hehlmann R, Baccarani M,
Guilhot F, Mahon FX, et al. Prognosis and prognostic
factors for patients with chronic myeloid leukemia:
nontransplant therapy. Semin Hematol 2003;40:4-12.
38.
Lee JP, Birnstein E, Masiello D, Yang D, Yang AS. Gender
and ethnic differences in chronic myelogenous leukemia
prognosis and treatment response: a single-institution
retrospective study. J Hematol Oncol 2009;2:30.
39.
Rajappa S, Varadpande L, Paul T, Jacob R, Digumarti R.
Imatinib mesylate in early chronic phase chronic myeloid
leukemia: Experience from a developing country. Leuk
Lymphoma 2008;49:554-8.
40.
Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S,
Ayala M, et al. Dasatinib versus imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia. N
Engl J Med 2010;362:2260-70.
41.
Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal
MB, Undurraga MS, et al. Dasatinib or imatinib in newly
diagnosed chronic-phase chronic myeloid leukemia: 2-
year follow-up from a randomized phase 3 trial
(DASISION). Blood 2012;119:1123-9.
42.
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G,
Lobo C, et al. Nilotinib versus imatinib for newly
diagnosed chronic myeloid leukemia. N Engl J Med 2010
17;362:2251-9.
43.
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn
IW, Stenke L, et al. Nilotinib versus imatinib for the
treatment of patients with newly diagnosed chronic phase,
Philadelphia chromosome-positive, chronic myeloid
leukaemia: 24-month minimum follow-up of the phase 3
randomised ENESTnd trial. Lancet Oncol 2011;12:841-51.
44.
Breccia M, Stefanizzi C, Cannella L, Latagliata R, Frustaci
AM, Carmosino I, et al. Differences in hematological and
non-hematological toxicity during treatment with imatinib